for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Bristol-Myers Squibb Co

BMY.N

Latest Trade

63.65USD

Change

-3.22(-4.82%)

Volume

2,127,464

Today's Range

63.61

 - 

66.73

52 Week Range

42.49

 - 

68.34

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
66.87
Open
66.37
Volume
2,127,464
3M AVG Volume
380.73
Today's High
66.73
Today's Low
63.61
52 Week High
68.34
52 Week Low
42.49
Shares Out (MIL)
2,344.19
Market Cap (MIL)
156,756.30
Forward P/E
--
Dividend (Yield %)
2.69

Next Event

Dividend For BMYMP.PK - 0.5000 USD

Latest Developments

More

U.S. FDA Accepts Priority Review For Bristol-Myers's Application For Opdivo Plus Yervoy

Nektar Therapeutics And Bristol-Myers Squibb Amend Collaboration Deal For Bempegaldesleukin Plus Opdivo

U.S. FDA Says Approves First Generics Of Eliquis

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Bristol-Myers Squibb Co

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. The Company's products include Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Hepatitis C Franchise, Reyataz Franchise and Sustiva Franchise. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience, and cardiovascular. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world. The Company’s subsidiary is Celgene Corp.

Contact Info

430 E 29th St Fl 14

+1.212.5464000

https://www.bms.com/

Executive Leadership

Giovanni Caforio

Chairman of the Board, Chief Executive Officer

Charles A. Bancroft

Chief Financial Officer, Executive Vice President - Global Business Operations

Ann Powell Judge

Chief Human Resource Officer, Senior Vice President

Sandra Leung

Executive Vice President, General Counsel

Christopher S. Boerner

Executive Vice President and Chief Commercial Officer

Key Stats

1.86 mean rating - 14 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

19.4K

2017

20.8K

2018

22.6K

2019(E)

24.4K
EPS (USD)

2016

2.830

2017

3.010

2018

3.980

2019(E)

4.382
Price To Earnings (TTM)
19.33
Price To Sales (TTM)
6.48
Price To Book (MRQ)
6.17
Price To Cash Flow (TTM)
24.37
Total Debt To Equity (MRQ)
141.43
LT Debt To Equity (MRQ)
138.20
Return on Investment (TTM)
16.07
Return on Equity (TTM)
12.47

Latest News

Latest News

Bristol-Myers confident of approvals linked to higher Celgene investor payout: Bristol executive

Bristol-Myers Squibb Co is confident it will receive U.S. approvals for all three experimental drugs tied to a potentially higher payout for Celgene shareholders under terms of its acquisition of the U.S. biotech company, Bristol's chief medical officer said.

FDA approves first generic of Bristol-Myers, Pfizer's blood thinner Eliquis

The U.S. Food and Drug Administration said on Monday it has approved the first generic version of Bristol-Myers Squibb Co and Pfizer Inc's blood thinner Eliquis.

Bristol-Myers wins $752 million in U.S. patent case against Gilead

Bristol-Myers Squibb Co on Friday said it won a $752 million jury verdict against Gilead Sciences Inc in a U.S. patent dispute relating to technology for treating cancer.

Bristol-Myers prevails over Gilead in Yescarta royalty row - Bloomberg Law

Bristol-Myers Squibb Co won a patent infringement trial against Gilead Sciences Inc's unit Kite Pharma over cancer immunotherapy Yescarta, Bloomberg Law reported on Friday.

Bristol-Myers business development head Biondi departs

Bristol-Myers Squibb Co's <BMY.N> head of strategy and business development Paul Biondi left the company last month just as it was completing its $74 billion acquisition of biotech Celgene Corp, the company said on Thursday.

Bluebird bio, Bristol-Myers' multiple myeloma therapy shows promise in early study

Bluebird bio Inc and Bristol-Myers Squibb Co on Monday reported encouraging initial data from an ongoing early-stage study testing their experimental therapy for multiple myeloma in patients who did not respond to prior treatments.

Bristol-Myers reports positive data on cancer treatment acquired in Celgene deal

Bristol-Myers Squibb Co on Saturday said that an experimental cancer therapy it acquired as part of its $74 billion deal for Celgene Corp produced positive results in a clinical trial.

UPDATE 1-Bristol-Myers, bluebird therapy for multiple myeloma succeeds in mid-stage trial

Bristol-Myers Squibb Co and bluebird bio Inc said on Friday their experimental therapy for a type of multiple myeloma met the main goal in a mid-stage study.

Bristol-Myers, bluebird therapy for multiple myeloma succeeds in mid-stage trial

Bristol-Myers Squibb Co and bluebird bio Inc said on Friday their experimental therapy for a type of multiple myeloma met the main goal in a mid-stage study.

Amgen raises 2019 profit, sales view after buying Celgene psoriasis drug

Amgen Inc <AMGN.O> on Thursday raised its full-year profit and revenue forecasts after completing its $13.4 billion acquisition of Celgene Corp's psoriasis therapy Otezla.

Bristol-Myers misses main goal of late-stage skin cancer trial

Bristol-Myers Squibb Co said on Wednesday a late-stage trial testing a combination of its cancer drugs missed a main goal of preventing skin cancer from recurring in a certain group of patients, sending its shares down nearly 1%.

Bristol-Myers misses main goal of late-stage skin cancer trial

Bristol-Myers Squibb Co said on Wednesday its late-stage trial testing a combination of its cancer drugs missed a main goal of preventing skin cancer from recurring in a certain group of patients.

Bristol-Myers Squibb wins antitrust approval to buy Celgene, but must divest psoriasis drug

Bristol-Myers Squibb Co and Celgene Corp have won U.S. antitrust approval for their merger on condition that they sell Celgene's psoriasis drug Otezla, the Federal Trade Commission said in a statement on Friday.

Bristol-Myers Squibb wins antitrust approval to buy Celgene on condition it sell psoriasis drug

Bristol-Myers Squibb Co and Celgene Corp have won U.S. antitrust approval for their merger on condition that they sell Celgene's psoriasis drug Otezla, the Federal Trade Commission said in a statement on Friday. (Reporting by Diane Bartz; Editing by Sandra Maler)

Bristol-Myers posts better-than-expected results, Opdivo growth slows

U.S. drugmaker Bristol-Myers Squibb Co <BMY.N> reported higher-than-expected third-quarter profit on Thursday, helped by strong sales of blood thinner Eliquis, even as growth of its blockbuster cancer treatment Opdivo slowed.

Bristol-Myers' immunotherapies show promise in lung cancer trial; shares rise

Bristol-Myers Squibb Co said on Tuesday an interim analysis of a late-stage trial testing a combination of its immuno-oncology drugs Opdivo and Yervoy met the main goal of extending life of previously untreated lung cancer patients.

Bristol-Myers immunotherapy combo outperforms chemo in lung cancer survival: study

About 40% of patients who received a combination of Bristol-Myers Squibb Co's immuno-oncology drugs Opdivo and Yervoy as an initial treatment for advanced non-small cell lung cancer (NSCLC) were alive after two years, according to data presented at a medical meeting on Saturday...

UPDATE 1-Bristol-Myers' Opdivo fails to meet goal of brain tumor study

Bristol-Myers Squibb Co said on Thursday its blockbuster cancer immunotherapy, Opdivo, failed to meet the main goal of a late-stage trial testing it in patients with a type of tumor that affects the brain and spine.

Amgen to buy Celgene's psoriasis drug Otezla for $13.4 bln in cash

Amgen Inc said on Monday it would buy Celgene Corp's psoriasis drug Otezla for $13.4 billion in cash, clearing the way for Bristol-Myers Squibb to go ahead with its $74 billion deal for Celgene.

Eliquis, Orencia sales propel Bristol-Myers to strong second quarter

Bristol-Myers Squibb Co <BMY.N>, which is set to buy biotechnology company Celgene Corp <CELG.O> for $74 billion, posted better-than-expected second-quarter profit on Thursday on strong sales of blood thinner Eliquis and rheumatoid arthritis treatment Orencia.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up